|
Market Closed -
Nasdaq
16:00:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 421.51 USD | -0.50% |
|
+3.80% | +28.78% |
| 09-30 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 09-28 | Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 229B | |||||
| 1,056B | |||||
| 645B | - | ||||
| 465B | |||||
| 368B | |||||
| 335B |
- Stock Market
- Stocks
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
